PEPTIDE GUIDE

What Is Melanotan II?

Melanotan II is a synthetic cyclic peptide designed to imitate some actions of alpha-melanocyte-stimulating hormone, a natural signalling molecule involved in pigmentation, appetite and other functions.

Early human experiments found that Melanotan II could darken skin and trigger erectile responses. It was never approved as a tanning medicine or sexual-dysfunction treatment. Products sold online as injections or nasal sprays have not been shown to match the research material in identity, purity or safety.

Research statusUnapproved melanocortin analogue with limited human research
Peptide typeCyclic melanocortin analogue
Human evidenceSmall early studies and case reports
ApprovalNot an approved medicine
Last reviewedSeptember 2026
THE SHORT ANSWER

Melanotan II is a seven-amino-acid cyclic melanocortin receptor agonist. An agonist is a molecule that activates a receptor. Small studies in the 1990s found increased skin pigmentation, while early studies in men reported erections as well as nausea, yawning and stretching. Those experiments did not establish a safe consumer tanning product. Melanotan II is not approved by the US Food and Drug Administration, normally shortened to FDA, or the UK Medicines and Healthcare products Regulatory Agency, normally shortened to MHRA. Regulators warn about unapproved products, and published case reports describe serious events including prolonged erection, systemic toxicity and possible renal infarction.

What is Melanotan II made from?

Melanotan II contains seven amino-acid residues arranged partly as a ring. Its structure is commonly written Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2.

Nle means norleucine, a designed amino-acid building block. D-Phe is a mirror-image form of phenylalanine. “Ac” shows that the beginning of the peptide is acetylated. The end is amidated, meaning it carries an amide group. A chemical link between side chains closes the central part of the molecule into a ring.

These changes make the peptide more stable and potent than the natural hormone fragment on which it was based. They also mean it is not simply purified from the human body.

What is alpha-melanocyte-stimulating hormone?

Alpha-melanocyte-stimulating hormone, usually shortened to alpha-MSH, is derived from a larger protein called proopiomelanocortin. It activates melanocortin receptors, a family of five receptor types labelled MC1 to MC5.

The melanocortin 1 receptor, or MC1 receptor, is important in pigment-producing cells called melanocytes. Activating it can increase production of eumelanin, a brown or black form of the pigment melanin.

Other melanocortin receptors participate in appetite, energy balance, sexual responses, inflammation and several organ systems. Melanotan II activates more than one receptor type. Its effects are therefore not confined to skin colour.

When was Melanotan II first documented?

Researchers at the University of Arizona developed melanocortin analogues during the 1980s while studying whether a stronger, longer-lasting version of alpha-MSH could increase protective skin pigmentation.

One linear analogue became known as Melanotan I and later as afamelanotide. Afamelanotide eventually became an approved medicine for a specific rare light-sensitivity disorder. Melanotan II was the shorter cyclic analogue. Approval of afamelanotide does not apply to Melanotan II.

A human Melanotan II study published in 1996 reported tanning after five exposures given on alternate days. Researchers also observed nausea, appetite changes, yawning and spontaneous erections. Those unexpected sexual effects led to further study and eventually to development of bremelanotide, also known as PT-141.

PeriodDevelopment
1980sMelanocortin analogues were designed to produce stronger and longer-lasting receptor activity
1996A small human study reported increased pigmentation and systemic effects from Melanotan II
1998 to 2000Small studies examined erectile responses in men
Early 2000sPT-141 was developed from the melanocortin programme
2007The FDA acted against US marketing of Melanotan II as an unapproved drug
2026Regulators continued enforcement and safety warnings concerning unapproved Melanotan II products

How is Melanotan II synthesised and manufactured?

Melanotan II is normally made by solid-phase peptide synthesis. Protected amino-acid building blocks are attached to a resin one at a time in the required order. Temporary chemical groups protect parts of each amino acid until the intended peptide bond has formed.

The ring is created by forming an amide bond between selected side chains. The peptide is then removed from the resin, deprotected and purified, usually by preparative high-performance liquid chromatography. High-performance liquid chromatography, usually shortened to HPLC, separates molecules according to how they move through a specialised column.

Mass spectrometry can confirm molecular mass. Additional testing is needed for peptide content, related impurities, residual solvents, water, counter-ions, sterility and bacterial endotoxins. A chromatogram advertised by a seller does not show that all of those standards have been met.

How does Melanotan II affect pigmentation?

Activation of the MC1 receptor can increase melanogenesis, the process by which melanocytes produce melanin. More eumelanin can darken skin and sometimes existing freckles or moles.

Pigmentation is not the same as protection from ultraviolet radiation. A tan provides limited protection and does not remove the DNA-damaging effects of ultraviolet exposure. Early development hoped that melanocortin analogues might reduce risk for people with specific light-related disorders, but Melanotan II did not become an approved preventive treatment for skin cancer.

The receptor mechanism also does not make every pigmented change harmless. Rapid change in a mole requires medical assessment regardless of whether a person believes a peptide caused it.

What did the early pigmentation study find?

The 1996 study was a small early human experiment rather than a large trial of long-term benefits and risks. Participants received five low exposures on alternate days. Researchers recorded increased pigmentation and examined how the body handled the peptide.

Nausea was common enough to affect development. Spontaneous erections, stretching and yawning showed that the compound was acting beyond pigment cells. These effects helped reveal melanocortin pathways involved in sexual response, but they also demonstrated why Melanotan II cannot be treated as a skin-only product.

Study design, not dosing guidance

The publication reports a research level of 0.025 milligrams per kilogram for future Phase 1 work and describes five alternate-day exposures. These facts explain the design of a small supervised study. They are not tanning instructions, and they do not validate online injections or sprays.

What did studies of erectile responses find?

In 1998, researchers studied men with erectile dysfunction thought to have a major psychological component. The publication reported erectile responses after Melanotan II, alongside nausea and other melanocortin effects.

A later crossover study involved 20 men. Crossover means participants receive more than one study condition at different times, allowing each person to contribute to both comparisons. In the absence of sexual stimulation, 17 of the 20 men had an erection after Melanotan II according to the study's measurement system.

These were small, short experiments. Melanotan II was not developed into an approved erectile-dysfunction medicine. PT-141, a related cyclic peptide now called bremelanotide, followed a separate development and regulatory path. Its approval for one form of low sexual desire in certain premenopausal women does not approve Melanotan II.

Is Melanotan II the same as PT-141?

No. The molecules are related but differ at the end of the peptide chain. PT-141 was developed to retain central melanocortin effects while reducing emphasis on pigmentation.

Bremelanotide became the active ingredient in the FDA-approved product Vyleesi. That product has a specified formulation, manufacturing process, label and narrow indication. None of those controls or approvals transfers to Melanotan II.

Is Melanotan II the same as afamelanotide?

No. Afamelanotide is the generic name for the linear 13-amino-acid analogue historically called Melanotan I, and it is the active medicine in Scenesse. It has regulatory approval for a specific disorder called erythropoietic protoporphyria in selected jurisdictions.

Melanotan II is a seven-amino-acid cyclic analogue. Evidence, safety monitoring and approval for afamelanotide cannot be used as evidence that Melanotan II is an approved tanning product.

What adverse effects appeared in research?

Early studies reported nausea, flushing, reduced appetite, yawning, stretching, tiredness and spontaneous erections. Darkening of freckles or moles can also occur because melanocytes are being stimulated.

The studies were too small and brief to measure uncommon or delayed harms. They predated widespread unsupervised use and cannot describe the quality or contamination risks of present-day online products.

An erection lasting several hours can become priapism, a medical emergency in which blood is trapped in the penis. Untreated ischaemic priapism can damage tissue and impair future function.

What serious events have been reported?

Case reports describe severe systemic toxicity, priapism requiring hospital treatment, a possible renal infarction and melanoma occurring after use. A renal infarction is an area of kidney tissue damaged because its blood supply is blocked.

A case report cannot prove that a substance caused an event. Other exposures, underlying risk and incomplete product testing can complicate the assessment. Case reports still matter when a product lacks large trials because they may reveal events that controlled research has not measured.

The relationship with melanoma remains unresolved. Stimulating pigmentation is biologically relevant, and several reports describe changing naevi, commonly called moles, or melanoma after use. Those observations do not establish causation, but they are not evidence of safety either.

What does the FDA say about compounded Melanotan II?

The FDA lists Melanotan II among bulk substances that may present significant safety risks in compounding. The agency points to possible immune reactions, aggregation and peptide-related impurities, as well as published serious case reports.

Aggregation means peptide molecules cluster together. This can change biological behaviour and increase the chance of an immune response. Active pharmaceutical ingredient characterisation is the work needed to show what molecule is present, in what amount and with which impurities.

The FDA record also shows that Melanotan II was treated as an unapproved new drug when marketed in the United States. “Research use only” wording does not turn a consumer product into an approved medicine.

What is the position in the United Kingdom and Australia?

Melanotan II is not an authorised tanning medicine in the United Kingdom. The MHRA has advised people who have used Melanotan II injections or nasal sprays to stop and seek professional advice if concerned about adverse effects.

Australia's Therapeutic Goods Administration, normally shortened to TGA, describes melanotan products as unapproved and warns against tanning products containing them. In May 2026, it announced enforcement action over alleged unlawful supply of Melanotan II.

Legal rules depend on jurisdiction and can change. Importation, supply, advertising and personal possession may be treated differently. Regulatory enforcement does not provide evidence that an unauthorised product is medically appropriate.

Why are nasal sprays not a proven safer alternative?

A different route changes absorption and exposure, but it does not remove the need for evidence. A nasal product may deliver an uncertain fraction of its contents through the nasal lining. Some may be swallowed, degraded or remain in the device.

There is no approved Melanotan II nasal product with established content, absorption and safety. Avoiding a needle does not resolve incorrect identity, contamination, dose variation or systemic melanocortin effects.

What benefits are claimed, and what does the evidence support?

ClaimWhat the evidence supports
Produces a tan without sun exposureSmall early studies show increased pigmentation, but not a safe approved consumer product
Protects against skin cancerNot established; pigmentation does not remove ultraviolet-related DNA damage
Treats erectile dysfunctionSmall early studies showed erectile responses; Melanotan II is not an approved treatment
Reduces appetite and body weightAppetite effects occurred, but no approved weight-management programme established benefit and safety
Nasal sprays are saferNot demonstrated in controlled product-specific trials
Online products match research materialCannot be assumed without reliable identity, purity and manufacturing controls

Which melanocortin receptors does Melanotan II affect?

The melanocortin family has five main receptors, named MC1R to MC5R. Melanotan II is not selective for only one of them.

MC1R is prominent in melanocytes, the cells that produce melanin pigment in skin and hair. MC3R and MC4R are found in the brain and participate in appetite, energy balance and sexual responses. MC5R has roles in several tissues, including some glands.

Acting at several receptors helps explain why a compound developed for pigmentation also caused nausea, reduced appetite, flushing and erections. It makes a simple “tanning peptide” description inaccurate.

Receptor activity measured in a laboratory does not show how much of a product reaches each human tissue. Exposure, breakdown and individual receptor variants all influence the response.

What did the pigmentation studies actually measure?

Early studies used measures such as reflectance, visual assessment and photographs to estimate changes in pigmentation. Reflectance measures how much light the skin returns. Darker skin generally reflects less visible light under standard conditions.

Small studies can show that a biological effect occurred, but they are less able to detect uncommon harms or describe the response across different skin types. Short follow-up cannot resolve whether pigment changes are even, how long they last or what repeated exposure does to melanocytic lesions.

The studies also used a known research preparation. Results cannot establish the contents or absorption of an online injection or nasal spray.

Does darker skin protect against ultraviolet radiation?

Melanin provides some natural protection by absorbing and dispersing ultraviolet radiation. It does not make skin immune to DNA damage. People with every skin tone can develop sunburn, photoageing and skin cancer.

An induced tan is evidence that pigment biology has changed. It is not evidence that ultraviolet exposure has become safe. Some tanning practices combine Melanotan II with sunbeds or intense sunlight, adding a known carcinogenic exposure to an unapproved product.

Ultraviolet A penetrates more deeply and contributes to photoageing. Ultraviolet B is a major cause of sunburn and direct DNA damage. Sunbeds can expose users to both. Sunscreen, clothing, shade and avoiding intense midday exposure remain relevant regardless of pigmentation.

What is the concern about moles and melanoma?

Case reports describe rapid darkening or change in existing moles after Melanotan II and instances in which melanoma was diagnosed after use. A case report documents what happened to one person. It cannot prove that the product caused the cancer.

Several explanations are possible. Receptor stimulation may darken an existing benign lesion. A melanoma might already have been present and become more noticeable. Ultraviolet exposure used alongside the product may contribute. An unregulated product might contain something other than the label states.

The absence of proof of causation is not reassurance. A new, changing, asymmetric or bleeding pigmented lesion needs medical assessment. Delaying assessment because a change is attributed to a tanning product could be harmful.

What do the erectile-response studies show?

Early studies found that Melanotan II could produce erections in some men with erectile dysfunction. Erectile dysfunction means persistent difficulty getting or maintaining an erection sufficient for sexual activity.

The finding helped establish melanocortin signalling as a route separate from the nitric-oxide pathway targeted by sildenafil. It also led researchers towards bremelanotide, a related molecule developed with a more focused clinical programme.

An induced erection is not automatically a successful treatment. Trials need to assess reliability, acceptability, nausea, blood pressure, sexual satisfaction and the risk of priapism. Priapism is an erection that persists and can damage tissue, particularly when blood cannot drain normally.

The approved bremelanotide evidence and label cannot be applied to Melanotan II. Their sequences, formulations, indications and safety programmes differ.

Why are case reports included if they cannot prove cause?

Randomised trials are best for estimating common benefits and harms, but small development programmes can miss rare serious events. Case reports can provide an early warning, especially when an event is unusual and follows exposure closely.

Melanotan II reports include prolonged erection, systemic toxicity, renal infarction and neurological illness. Renal infarction means loss of blood supply to part of a kidney. A sympathomimetic toxidrome is a pattern such as agitation, fast heart rate, high blood pressure and raised temperature that resembles excessive stimulation of the sympathetic nervous system.

Each report must be interpreted cautiously because product identity and other exposures may be uncertain. Together with absent approval and poor product control, they support caution rather than a precise estimate of risk.

What would adequate long-term research require?

A modern programme would need a defined pharmaceutical product, skin-type representation and dermatological examinations before and after treatment. Researchers would record every changing lesion and use independent assessment.

Cardiovascular monitoring would examine blood pressure and heart rate. Sexual-function studies would use validated measures and urgent reporting of prolonged erections. Trials would also need follow-up long enough to examine pigmentation, eye effects and tumour outcomes.

No consumer Melanotan II product has supplied that evidence package.

Does Melanotan II cause weight loss?

Nausea and reduced appetite were observed in early research, consistent with activity at central melanocortin receptors. Losing weight while feeling unwell is not evidence of a safe obesity treatment.

An obesity programme would need to measure weight over months, body composition, metabolic health, treatment discontinuation and what happens after treatment stops. It would also need to compare the compound with established care.

Melanotan II has no approved weight-management indication and no dependable modern programme showing that its overall benefits outweigh its risks for obesity.

Why does nasal delivery not remove systemic risk?

The nasal lining contains blood vessels, and substances absorbed there can enter the circulation. Variable nasal absorption makes exposure less predictable, not necessarily safer.

Congestion, spraying technique, formulation acidity and mucosal damage can change absorption. Peptide sprays also need preservatives, microbial control and stability testing. A label claiming a measured amount per spray does not prove that each spray delivers or absorbs that amount.

If enough Melanotan II is absorbed to darken skin or affect appetite, it may also reach receptors associated with nausea, blood pressure and sexual responses. Route does not make a non-selective receptor agonist selective.

What should a source say before its claims are credible?

A useful study identifies the amino-acid sequence, salt form, formulation and manufacturer. It reports who participated, how groups were assigned, what comparison was used and how long follow-up lasted.

It also reports withdrawals and adverse events, not only photographs or pigment scores. For skin safety, independent dermatological assessment and documentation of existing lesions are important.

Commercial pages that cite a receptor mechanism without describing a controlled human outcome have not supplied clinical evidence.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

Is Melanotan II a peptide?

Yes. It is a synthetic cyclic peptide containing seven amino-acid residues.

Is Melanotan II FDA approved?

No. It is not an FDA-approved tanning medicine or treatment for sexual dysfunction.

Does Melanotan II make skin darker?

Small human studies reported increased pigmentation. That finding does not establish long-term safety or protection from ultraviolet damage.

Is Melanotan II the same as PT-141?

No. They are related cyclic melanocortin peptides but are different molecules with different development histories.

Is Melanotan II the same as afamelanotide?

No. Afamelanotide is a different, longer analogue used in a regulated medicine for a specific rare condition.

Can Melanotan II change moles?

Darkening or change in pigmented lesions has been reported. A new or changing mole needs clinical assessment rather than an assumption about its cause.

Can Melanotan II cause prolonged erections?

Yes. Erections occurred in early research, and case reports describe ischaemic priapism requiring urgent treatment.

Are Melanotan II nasal sprays approved?

No approved Melanotan II nasal spray has established product quality, absorption and safety.

How is Melanotan II made?

It is assembled from protected amino-acid building blocks, cyclised, purified and tested using analytical methods.

Is Melanotan II a safe alternative to sunbeds?

Available evidence does not establish it as a safe tanning method. It also does not make ultraviolet exposure harmless.

What the evidence supports today

Melanotan II established that a compact cyclic melanocortin peptide could change pigmentation and sexual responses in people. That scientific history helped lead to other compounds, including bremelanotide.

It did not produce an approved tanning medicine. Human studies were small, side effects were common and modern online products are not demonstrated to be equivalent to the research preparations. Serious case reports and regulatory warnings add to the uncertainty.

A complete modern programme would need a defined formulation, controlled comparisons, dermatological monitoring, cardiovascular assessment and long follow-up. That evidence is not available for consumer Melanotan II products.

RESEARCH AND MEDICAL NOTICE

This guide describes research and regulatory information. It does not recommend Melanotan II, tanning injections or nasal products. It does not provide dosing, administration, cycling or purchasing guidance.

Research reviewed through September 2026.